Every 10-Q that Talphera, Inc. (TLPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TLPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLPH filings page.
Talphera, Inc. reported another loss-making quarter as it continues to focus all resources on developing its nafamostat-based anticoagulant Niyad for dialysis settings. For the three months ended June 30, 2026, the company recorded a net loss of $4.3 million, compared with $3.5 million a year earlier; the six‑month net loss was $6.9 million.
Cash, cash equivalents and short‑term investments totaled $17.1 million as of June 30 2026, down from $20.4 million at year‑end, after using $7.3 million in operating cash in the first half and raising $3.8 million via a private placement of common stock and pre‑funded warrants. The NEPHRO CRRT registrational trial of Niyad is ongoing, with enrollment completion expected in 2026.
Management states that recurring losses, negative operating cash flows and limited cash resources raise substantial doubt about Talphera’s ability to continue as a going concern. The company expects to need additional capital to fund planned operations within 12 months of the report’s filing and outlines potential equity, debt, partnering or asset‑monetization options, while noting these plans are not within its full control.
Talphera, Inc. reports a Q1 2026 net loss of $2.6 million, similar to the prior-year period, as it continues investing in Niyad, its nafamostat-based anticoagulant for dialysis circuits. Research and development expenses rose to $1.7 million and selling, general and administrative costs to $2.3 million, reflecting higher trial activity and corporate spending.
Cash, cash equivalents and short-term investments totaled $21.1 million as of March 31, 2026, slightly above year-end, helped by $4.1 million of gross proceeds from a private placement of common stock and pre-funded warrants. The company discloses “substantial doubt” about its ability to continue as a going concern and expects to need additional capital within 12 months to fund operations.
Talphera’s NEPHRO CRRT registrational trial for Niyad is ongoing, with completion expected in 2026. The FDA has granted Niyad Breakthrough Device Designation, but Niyad and related nafamostat programs remain pre-revenue. Talphera also notes a Nasdaq notice for failing to maintain the $1.00 minimum bid price requirement, which does not immediately affect its listing but adds execution risk around future financing and shareholder value.
Talphera, Inc. is advancing nafamostat-based product candidates and is funded through recent equity financings. The company reports 200,000,000 shares authorized and 20,522,655 shares issued and outstanding as of June 30, 2025, up from 17,029,469 at December 31, 2024. Its lead developmental product, Niyad, a lyophilized formulation of nafamostat, is being studied under an IDE and has received FDA Breakthrough Device Designation for regional anticoagulation in continuous renal replacement therapy; nafamostat is approved in Japan and South Korea for related uses. Talphera also acquired LTX-608, a nafamostat IV formulation for potential ARDS, DIC, acute pancreatitis or antiviral use. A securities appeal remains pending after dismissal of plaintiffs’ case; briefing completed January 21, 2025 and oral argument occurred June 12, 2025. The company completed a private placement that included 4,999,316 pre-funded warrants exercisable at $0.001 and other financing activity disclosed.